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Background and PurposezzAmyotrophic lateral sclerosis (ALS) patients display easy fatiga-
bility and abnormal decrements on repetitive nerve stimulation (RNS) test of clinically involved 
limb muscles, which can result in ALS being misdiagnosed as myasthenia gravis. We retrospec-
tively analyzed the RNS tests of ten ALS patients with only or predominant oropharyngeal symp-
toms without ocular or facial weakness.
MethodszzRNS tests were performed on the abductor digiti quinti, flexor carpi ulnaris, orbicu-
laris oculi (OO), nasalis and trapezius muscles at low-rate stimulation frequencies of 3 and 5-Hz. 
Decrements greater than 10% of the compound muscle action potential amplitude on the fifth 
stimulation compared to the first was regarded as abnormal.
ResultszzSix patients complained of muscular fatigue or diurnal fluctuation. Among the ten pa-
tients, three exhibited abnormal decrements during low-rate stimulation in the facial muscles but 
not in the limb muscles, two exhibited abnormal decrements in the OO and nasalis muscles, and 
one exhibited abnormal decrements in the OO muscle.
ConclusionszzThese findings show that the facial muscles may be involved in some early oro-
pharyngeal forms of ALS, although facial weakness may not be clinically evident. We confirm 
herein that abnormal decrement of facial muscles to RNS test cannot make a definite diagnose for 
myasthenia gravis. J Clin Neurol 2011;7:31-33
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Introduction
Repetitive nerve stimulation (RNS) test is fundamentally an elec-
trophysiologic study for the differential diagnosis of neuromus-
cular junction (NMJ) disorders, although there are considerable 
limitations in its diagnostic sensitivity and specificity. Amyo-
trophic lateral sclerosis (ALS) is occasionally misdiagnosed 
as myasthenia gravis (MG), showing prominent bulbar mus-
cle weakness without definite atrophy of the limb muscles, or 
fasciculation. Although ALS is not primarily a disease of the 
NMJ, there have been several reports of fatigable weakness 
and RNS abnormalities, especially of clinically involved mus-
cles.1-6 Significant decrements in the facial muscles such as the 
orbicularis oculi (OO) or nasalis (NA) muscles have only rare-
ly been reported in ALS patients.7
The clinical significance of the RNS test was determined in 
this study by retrospectively analyzing the RNS tests of ALS pa-
tients with only or predominant oropharyngeal manifesta-
tions.
Methods
The data of ten patients were analyzed after the diagnosis of 
ALS was established. They visited the electrophysiology lab-
oratory in the Department of Neurology at Sinchon Severance 
hospital with predominant oropharyngeal symptoms between 
January 1997 and December 2008. The serum titer of acetyl-
choline receptor antibody was measured in five patients. The 
diagnosis of ALS was confirmed by the clinical course and fol-
low-up electrophysiologic studies.
RNS test was performed on the facial nerve with a recording 
electrode over the OO and NA muscles, on the spinal accesso-
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ry nerve with a recording electrode over the upper trapezius 
muscle, and on the ulnar nerve with the recording electrode 
over the flexor carpi ulnaris and abductor digiti quinti muscles, 
using the belly-tendon method. The changes in compound 
muscle action potential (CMAP) amplitude followed by 3- and 
5-Hz supramaximal low-rate stimulation (LRS) were analyzed. 
For each train of repetitive stimuli, the amplitudes of the first 
and fifth CMAPs were compared, and the resulting decrement 
of the latter (if present) is expressed as a percentage. Decre-
ments greater than 10% were considered as abnormal accord-
ing to the guidelines of American Academy of Emergency 
Medicine Quality Assurance committee.8
Results
Six of the ten patients were women and their mean age was 
55.3 years (range: 42-68 years). The mean duration of symp-
toms was 9.7 months (range: 2-36 months). All of the patients 
complained of only or predominant oropharyngeal symptoms 
including dysarthria, dysphagia and/or nasal voice. In addition 
to these oropharyngeal symptoms, one patient (case 1) compla-
ined of intermittent clumsiness of both hands of 1-month dura-
tion, and another (case 7) had experienced difficulty elevating 
the head for 1 month. None of the patients showed any clinical 
evidence of facial muscle weakness, ptosis or diplopia. Six pa-
tients complained of muscular fatigue or diurnal fluctuation, 
and two patients (cases 7 and 9) had been previously diagnosed 
and treated for MG (Table 1).
Abnormal decrements during 3-Hz LRS on more than one fa-
cial muscle were noted in three patients (30.0%): in two patients 
(cases 2 and 7) in both the OO and NA, and in one (case 9) in 
the OO. Borderline decrements (9.7%) during 5-Hz LRS were 
recorded in the NA in one other patient (case 10). None of the 
patients showed any abnormal decrements in the limb muscles.
Discussion
While the clinical course is very important for the differential 
diagnosis of ALS and MG, the pharmacologic response to an-
ticholinesterase, the determination of anti-acetylcholine recep-
tor antibody titer and electrophysiologic studies including the 
RNS test are the main ways of ensuring a differential diagnosis.
There are several reports of significant decrements on RNS 
test of involved limb muscles in ALS.1-6 Denys et al.2 proposed 
a relationship between muscle atrophy and decremental re-
sponses. However, Bernstein et al.3 reported that disease activi-





Sex Chief complaints Fatigue*
RNS test AChR  
AbADQ FCU OO NA TR
1 EJN 57 F Dysarthria (12 months), clumsy  
  hand movement (1 month)
+ -3.3 -6.1 2.6 0 1.1 0.01
2 LYP 47 M Nasal voice, dysarthria  
  (2 months)
+ 0 0 -15.7† -13.0† -4.8 0.01
3 CYH 50 M Dysarthria, dysphagia  
  (7 months)
+ 0 0 1.4 0 -1.8
4 SKN 42 F Slowly progressing dysarthria,  
  dysphagia (36 months)
– ND ND -5.4 -1.5 ND
5 KJY 55 F Dysarthria (8 months),  
  nasal voice (2 months)
+ -6.2 -6.5 10.0 4.8 5.6 0.09
6 SYJ 59 F Dysarthria (4 months),  
  left toe weakness (1 month)
– -0.6 -1.0 -9.3 -3.7 -5.2
7§ SYG 54 M Dysarthria (8 months),  
  neck weakness (1 month)
– 1.0 -2.8 -12.0† -17.6† -9.0 0.01
8 SJB 68 M Dysarthria (12 months),  
  dysphagia (3 months)
– 0.7 -3.9 -3.5 -7.4 -6.8
9§ YMS 68 F Dysarthria (4 months),  
  dysphagia (2 months)
+ 1.1 -2.3 -14.0† -8.3 -7.1 0.09
10 KYS 53 F Hoarseness (4 months),  
  dysphagia (3 months),  
  dysarthria, nasal voice  
  (2 months)
+ -0.9 -9.3 -7.9 -9.7‡ -5.1
*+: Present, –: Absent, †Abnormal decrement greater than 10% on RNS test, ‡Borderline abnormal decrement on RNS test, §Previously 
diagnosed and treated for MG.
AChR Ab: acetylcholine receptor antibody, ADQ: abductor digiti quinti muscle, F: female, FCU: flexor carpi ulnaris muscle, M: male, NA: 
nasalis muscle, ND: no discharge, OO: orbicularis oculi muscle, TR: trapezius muscle.
Kim JY et al.
www.thejcn.com  33
ty and speed of progression might be more important factors 
for these findings. Restivo et al.7 reported significant decre-
ments in facial muscles in one ALS patient, but this case seem-
ed to be a true MG patient with ALS, as evidenced by seroposi-
tivity and abnormal decrements in the deltoid muscle.
Abnormal decrements on RNS test suggest the presence of 
instability of neuromuscular transmission in ALS. The under-
lying pathogenesis of NMJ instability remains unclear, but the 
following hypotheses have been proposed. First, motor neuron 
death causes enlargement of the motor unit territory by collat-
eral sprouting, leading to a reduced safety factor for the NMJ in 
re-innervated end plates.2,3,5 Second, neuronal degeneration in 
ALS might disturb axonal transport of the synthetic enzyme 
choline acetyltransferase.1,3 Third, pathologic changes occur in 
the NMJ in ALS, as identified in a few muscle biopsies and an-
imal studies.2,9-11
Our results suggest that the facial muscles are involved in 
some ALS patients with prominent oropharyngeal symptoms, 
although facial weakness may not be clinically evident. It is un-
derstandable that abnormal decremental responses were not re-
corded in the flexor carpi ulnaris, abductor digiti quinti, and 
trapezius muscles, because these muscles were not involved at 
the time of RNS tests. We believe that our patients are not true 
MG cases because of their seronegativity for MG and poor re-
sponse to anticholinesterase treatment, as well as their clinical 
courses. However, it is difficult to reach a firm conclusion be-
cause this study was retrospective and included only a small 
number of subjects. For example, it might be inferred that the 
three patients who exhibited decrement in the facial muscles 
presented oropharyngeal manifestations more rapidly than the 
others. Therefore, the speed of disease progression might be 
associated with neuromuscular instability in ALS, as indicated 
by Bernstein et al.3 Further comparative studies with larger co-
horts of ALS patients are required to clarify this.
In summary, the facial muscles may be involved in ALS with 
predominant oropharyngeal symptoms, although facial weak-
ness may not be observed clinically. This study makes clear 
that we cannot simply diagnose MG because the significant 
decrement of facial muscles is observed to low-rate RNS test.
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